The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A Trial
Authors:
- Andre LamyALAndre Lamy
- Wesley TongWTWesley Tong
- Peggy GaoPGPeggy Gao
- Susan ChrolaviciusSCSusan Chrolavicius
- Amiram GafniAGAmiram Gafni
- Salim YusufSYSalim Yusuf
- Stuart J. ConnollySCStuart J. Connolly
- 1 January 2012
- journal article
- research article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 28 (1) , 95-101
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: The appropriate use and barriers to oral anticoagulant therapyThrombosis Research, 2007
- Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular eventsAmerican Heart Journal, 2006
- Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevationAmerican Heart Journal, 2006
- Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate AnticoagulationJACC, 2005
- Atrial fibrillation in patients with first‐ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcomeJournal of Thrombosis and Haemostasis, 2005
- Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic StrokeStroke, 2005
- Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevationJACC, 2005
- Cost of stroke in Canada: a 1-year prospective studyJournal of Medical Economics, 2005
- The death of cost‐minimization analysis?Health Economics, 2001
- Cost Analysis of the Treatment of Schizophrenia in the UKPharmacoEconomics, 1998